This is a translation of the original article in Portuguese. Read the original (Português).
The Watchman, a device used to prevent strokes in people with atrial fibrillation, has come under scrutiny in the United States. A report by the American newspaper The Boston Globe says the manufacturer, Boston Scientific, promoted the device aggressively and paid more than US$30 million to doctors in consulting fees and training programs. Cardiologists interviewed by the newspaper say it has been used excessively. The company denies that the device is applied beyond its approved indications.
The Watchman closes the left atrial appendage, a part of the heart where clots form in patients with atrial fibrillation, a type of arrhythmia. The idea is to offer an alternative to anticoagulants, medications that reduce the risk of stroke but can cause bleeding.
Two recent studies help measure what the device delivers. The Closure trial, a German study, found more strokes, clots and bleeding among patients with the Watchman or the competing device Amulet than among those treated with anticoagulants.
The Champion trial, funded by Boston Scientific itself, showed that the Watchman was not inferior to drug treatment. But the group that received the device had more ischemic strokes, those caused by blockage of a blood vessel. According to The Boston Globe, the studies indicate that the device is not always better than anticoagulants.
After the results were released, sales of the Watchman slowed sharply. The company responded with more direct-to-consumer advertising. According to ISpot, a company that measures advertising, spending on TV commercials jumped from about US$111,000 in 2022 to US$8.1 million in 2025. Experts criticize the strategy and say the evidence on the device is still weak.
Why it matters
The case matters to people living with the condition. Atrial fibrillation is common among people over 50, and the choice between the device and an anticoagulant affects both the patient’s health and finances. The combination of TV ads and payments to doctors shows how marketing can enter a decision that should be purely clinical.
The Boston Globe does not address Brazil. For Brazilian patients, the practical lesson is to talk with their cardiologist about the options, ask what the risks of each are, and whether the doctor has any relationship with the manufacturer.
Reporting from Boston Globe (p. 14, Boston (Estados Unidos): publicidade de TV do Watchman), Boston Globe (p. 15: estudos Closure e Champion e queda nas vendas), Boston Sunday Globe (p. 12: reportagem investigativa sobre uso excessivo e pagamentos a médicos).
Deixe um comentário